- $10.73bn
- $10.42bn
- $738.26m
Brief: Repligen Q1 Adj. EPS $0.64
Brief: Repligen Reports First Quarter 2023 Financial Results And Updates Full Year 2023 Financial Guidance
Repligen Corp expected to post earnings of 59 cents a share - Earnings Preview
Brief: Repligen Corp Says, On April 12, Co Executed Equity Purchase Agreement With Flexbiosys Inc, Tsap Holdings Inc - Filing
U.S. RESEARCH ROUNDUP- Marathon Petroleum, Nvidia, Repligen
Repligen Corp reports results for the quarter ended in December - Earnings Summary
Brief: Repligen Reports Fourth Quarter 2022 Financial Results
Brief: Repligen Reports Q4 Adjusted Net Income of USD 39.1 million
Repligen Corp expected to post earnings of 58cents a share - Earnings Preview
Medical tool makers fall after Danaher cuts growth expectations for unit
U.S. RESEARCH ROUNDUP- Autozone, Nike, Sachem Capital
Repligen Corp reports results for the quarter ended in September - Earnings Summary
Brief: Repligen Corp Reports Quarterly Earnings Per Share Of $0.71
Brief: Repligen Extends And Expands Long-Term Supply Agreement With Purolite For Affinity Ligands
Repligen Corp expected to post earnings of 68cents a share - Earnings Preview
Brief: Repligen Expands Process Analytics Portfolio With DRS Daylight Solutions Agreement
U.S. STOCKS ON THE MOVE-Repligen, Tesla, Harmony Biosciences
Repligen jumps on upbeat Q2 results, 2022 forecast raise
Brief: Repligen Corp Posts Q2 GAAP EPS $0.88